NCT03282461View on ClinicalTrials.gov

A Microdose Evaluation Study of ABY-029 in Head and Neck Oncology Surgery

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 24, 2018

Primary Completion Date

December 18, 2020

Study Completion Date

December 18, 2020

Conditions
Head and Neck Cancer
Interventions
DRUG

ABY-029

A sample size of 6-12 patients in this open label, single center, clinical trial of ABY-029. Administration will occur as a single intravenous injection to subjects with operable head and neck cancer approximately 1-3 hours prior to surgery.

Trial Locations (1)

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
collaborator

Dartmouth College

OTHER

lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT03282461 - A Microdose Evaluation Study of ABY-029 in Head and Neck Oncology Surgery | Biotech Hunter | Biotech Hunter